Opportunity cost. The deal wont close for months and with the spec market looking good many will feel they could make more elsewhere.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025